메뉴 건너뛰기




Volumn 3, Issue 11 SUPPL. 3, 1999, Pages

Implementation of fixed-dose combinations in tuberculosis control: Outline of responsibilities

(1)  Chaulet, P a  

a NONE   (Algeria)

Author keywords

Antituberculosis drugs; Bioavailability; Fixed dose combinations

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; THIOACETAZONE; TUBERCULOSTATIC AGENT;

EID: 0032751242     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper
Times cited : (9)

References (10)
  • 3
    • 0004772352 scopus 로고    scopus 로고
    • Essential drugs: WHO model list Revised Decemher 1997
    • World Health Organization. Essential Drugs: WHO Model List (revised Decemher 1997. WHO Drug Information. 1998; Vol 12, No 1: 22-35.
    • (1998) WHO Drug Information , vol.12 , Issue.1 , pp. 22-35
  • 4
    • 0032711755 scopus 로고    scopus 로고
    • The evaluation of rifampicin bioavailabilities of fixed-dose combinations of anti-tuberculosis drugs: Procedures for ensuring laboratory proficiency
    • Ellard G. The evaluation of rifampicin bioavailabilities of fixed-dose combinations of anti-tuberculosis drugs: procedures for ensuring laboratory proficiency. Int J Tuberc Lung Dis 1999; 3 (Suppl 3): S322-S324.
    • (1999) Int J Tuberc Lung Dis , vol.3 , Issue.SUPPL. 3
    • Ellard, G.1
  • 5
    • 0032737204 scopus 로고    scopus 로고
    • Rifampicin bioavailability: A review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption
    • Ellard G A, Fourie P B. Rifampicin bioavailability: a review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption. Int J Tuberc Lung Dis 1999; 3 (Suppl 3): S301-S308.
    • (1999) Int J Tuberc Lung Dis , vol.3 , Issue.SUPPL. 3
    • Ellard, G.A.1    Fourie, P.B.2
  • 7
    • 11944261115 scopus 로고
    • Guiding principles for small national drug regulatory authorities
    • Appendix 1. Geneva: WHO
    • World Health Organization. Guiding principles for small national drug regulatory authorities. In: WHO Expert Committee, fifth report. WHO Technical Report Series, no 825, Appendix 1. Geneva: WHO, 1992.
    • (1992) WHO Expert Committee, Fifth Report. Who Technical Report Series, No , vol.825
  • 9
    • 0344374439 scopus 로고    scopus 로고
    • Requirements for anti-tuberculosis drug tender requests
    • Trébucq A, Caudron J M, Pinel J. Requirements for anti-tuberculosis drug tender requests. Int J Tuberc Lung Dis 1999; 3 (Suppl 3): S358-S361.
    • (1999) Int J Tuberc Lung Dis , vol.3 , Issue.SUPPL. 3
    • Trébucq, A.1    Caudron, J.M.2    Pinel, J.3
  • 10
    • 0032757771 scopus 로고    scopus 로고
    • Assuring bioavailability of fixed-dose combinations of anti-tuberculosis medications
    • International Union Against Tuberculosis and Lung Disease/ World Health Organization. Assuring bioavailability of fixed-dose combinations of anti-tuberculosis medications. Int J Tuberc Lung Dis 1999; 3 (Suppl 3): S282-S283.
    • (1999) Int J Tuberc Lung Dis , vol.3 , Issue.SUPPL. 3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.